Despite the current standard of multimodal management, glioblastoma (GBM) inevitably recurs and effective therapy is not available for recurrent disease. A subset of tumor cells with stem-like properties, termed GBM stem-like cells (GSCs), are considered to play a role in tumor relapse. Although oncolytic herpes simplex virus (oHSV) is a promising therapeutic for GBM, its efficacy against recurrent GBM is incompletely characterized. Transforming growth factor beta (TGF-b) plays vital roles in maintaining GSC stemness and GBM pathogenesis. We hypothesized that oHSV and TGF-b inhibitors would synergistically exert antitumor effects for recurrent GBM. Here we established a panel of patient-derived recurrent tumor models from GBMs that relapsed after postsurgical radiation and chemotherapy, based on GSC-enriched tumor sphere cultures. These GSCs are resistant to the standard-of-care temozolomide but susceptible to oHSVs G47D and MG18L. Inhibition of TGF-b receptor kinase with selective targeted small molecules reduced clonogenic sphere formation in all tested recurrent GSCs. The combination of oHSV and TGF-bR inhibitor was synergistic in killing recurrent GSCs through, in part, an inhibitor-induced JNK-MAPK blockade and increase in oHSV replication. In vivo, systemic treatment with TGF-bR inhibitor greatly enhanced the antitumor effects of single intratumoral oHSV injections, resulting in cures in 60% of mice bearing orthotopic recurrent GBM. These results reveal a novel synergistic interaction of oHSV therapy and TGF-b signaling blockade, and warrant further investigations aimed at clinical translation of this combination strategy for GBM patients.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. 1 Despite the current standard management including surgery followed by radiotherapy and temozolomide chemotherapy, GBM remains lethal with median survival of only 14.6 months. 2 The refractory nature of GBM is characterized by its inevitable recurrence after intensive multimodality therapy. Once GBM recurs, median survival is only 4-7 months. 3, 4 Thus far, exploratory clinical investigations of a variety of molecular targeted and antiangiogenic agents have failed to achieve enduring effects or overall survival benefit. 5 The culprit may be a subpopulation of GBM cells termed GBM stem-like or initiating cells (GSCs) possessing stem-like properties and sustaining tumor growth. 6 GSCs may survive cytotoxic therapy due to their inherent resistant phenotype and propagate recurrent disease. Thus GSCs represent a critical therapeutic target. In addition, patient-derived GSCs maintain patient-specific genetic and phenotypic alterations, and provide clinically representative GBM models suitable for therapeutic development. 7, 8 However, there is a paucity of the preclinical models of recurrent GBM that are based on patient-derived GSCs. Oncolytic herpes simplex virus (oHSV) is a genetically engineered HSV that selectively replicates and kills cancer cells, while leaving non-neoplastic cells unharmed. 9 oHSVs have been extensively studied in both preclinical and clinical settings as a potential therapeutic for GBM. Early clinical trials that assessed oHSVs for malignant gliomas demonstrated the safety and feasibility of inoculating oHSV into the human brain, but their efficacy remains anecdotal. 9 Maximizing the therapeutic potential of oHSV will likely require its use in conjunction with other anticancer modalities such as chemotherapeutics or molecular targeted agents. 10 In fact, our group has reported beneficial or synergistic anti-GBM effects by oHSV combinations with cytotoxic chemotherapeutics, 11, 12 PI3kinase inhibitors 13 and antiangiogenic agents, 14, 15 via distinct mechanisms of action in orthotopic GSC GBM models. Although in the past recurrent GBM tended to be the primary target for oHSV clinical trials, the activity of oHSV against recurrent GBM has not been preclinically validated in detail. Selective targeting of signaling pathways critical for GSC maintenance or resistance might provide a means for novel combination strategies with oHSV to enhance efficacy in the treatment of refractory, recurrent GBM.
The transforming growth factor beta (TGF-b) family of cytokines, TGF-1, 2 and 3, have diverse functions in the pathogenesis of cancer including GBM. [16] [17] [18] TGF-b1 and 2 are highly expressed in malignant gliomas and association with poor prognosis has been reported. 19, 20 TGF-b interacts with its cognate cell surface receptor tyrosine kinase TGFbR2, which forms heterodimers with TGF-bR1 (also termed ALK5) and activates both canonical signaling pathways through phosphorylating the signaling transducer Smads and noncanonical pathways such as MAP kinase pathways. TGFb signaling drives a variety of malignant phenotypes of GBM, including invasion/migration, angiogenesis, drug/radiation resistance and immune suppression. 17, 18 Importantly, accumulating evidence indicates that TGF-b signaling plays a vital role in the maintenance of GSC stemness and promotes GBM oncogenesis. 21, 22 These observations support the TGFb signaling pathway as a promising therapeutic target in GBM and its GSC subpopulation. As such, a number of small molecule inhibitors of TGF-bR kinases (hereafter abbreviated as TbR) are in preclinical and clinical development. TbR inhibition by the selective TbRI/II dual small molecule inhibitor LY2109761 radiosensitized GSCs and combination treatment of radiation and LY2109761 extended survival in orthotopic GSC-derived GBM in mice. 23 A first-in-human dose study of the TbR1 kinase inhibitor galunisertib (LY2157299) revealed its safety, 24 and early phase clinical trials evaluating galunisertib for GBM are ongoing. 25 This study was devised to address our hypothesis that oHSV and TbR inhibitors would synergistically exert antitumor effects for recurrent GBM. Using a panel of patientderived recurrent GBM models based on GSC-enriched tumor sphere cultures isolated from recurrent GBM resections, we show antitumor effects of targeted TbR inhibition and oHSV. Furthermore, combination treatment of TbR inhibitor and oHSV is synergistic in vitro, and mediates markedly enhanced therapeutic effects for recurrent GSC GBM models in vivo.
MATERIAL AND METHODS

Cells and xenograft models
Eight recurrent GSC lines (MGG24R, MGG31, MGG45, MGG50, MGG85, MGG91. MGG111R, MGG123) were established from GBMs that recurred after standard adjuvant therapy including surgical resection, radiotherapy and temozolomide chemotherapy, and these are referred to as recGSCs. Primary GSCs (MGG4, MGG8 and MGG64) were established from newly diagnosed GBMs, 7, 8 and termed as newly diagnosed GSCs. Tissue collection was approved by the Institutional Review Board at Massachusetts General Hospital, and the method to initiate culture has been previously described. 7 All GSCs were cultured as neurospheres in defined serum free media supplemented with EGF and FGF-2. 7 Vero cells (African green monkey kidney cells) were obtained from the American Type Culture Collection, and cultured in Dulbecco's Modified Eagle's Medium (DMEM; Mediatech) supplemented with 10% calf serum. GSCs were intracerebrally implanted in SCID mice (NCI) as described 7, 8 and mice were euthanized when they developed significant neurological deficits or general condition deterioration (e.g., >15% body weight loss) for brain collection and pathological studies. EGFR copy number was determined by FISH as described. 26, 27 Targeted sequencing using SNapShot genotyping was used to detect hotspot mutations in TP53 and PTEN. 27 What's new? Glioblastoma (GBM) is an aggressive disease with a high proclivity for relapse despite intensive multimodal therapy. GBM stem-like cells (GSCs), which sustain tumor growth, are central to recurrence. This study shows that recurrent GSCs are susceptible to killing through combined treatment with oncolytic herpes simplex virus (oHSV) and a transforming growth factor beta receptor (TGF-bR) inhibitor. In GSC-enriched tumor spheres, GSC killing effects were found to be mediated in part through inhibitor-induced JNK-MAPK blockade and elevated oHSV replication. TGF-bR inhibition further enhanced oHSV therapeutic efficacy in mice with orthotopic recurrent GBM, with long-term tumor-free survival in 60 percent of animals.
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. 13 All viruses were grown, purified and titered on Vero cells.
Reagents SB431542 (Sigma-Aldrich), LY2109761 (Selleckchem, Houston, TX) and galunisertib (LY2157299, Selleckchem) are selective and reversible inhibitors of the TGF-b receptor type I kinase. Selective and reversible JNK inhibitor SP600125 and the alkylating agent temozolomide were from Sigma-Aldrich. All the regents were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich). Recombinant human TGF-b1 (Peprotech) was dissolved in 0.1 M citric acid.
Immunohistochemistry
Immunohistochemistry (IHC) for CD44 (Anti-CD44 from Cell Signaling Technology), human nestin (Santa Cruz) and YKL-40 (Quidel) was performed on formalin-fixed paraffinembedded sections using the protocol described previously 7 with slight modifications. For antigen retrieval, 0.1% saponin (Sigma) treatment for 5 min was used for CD44 and YKL-40, and microwave in citrate buffer for human nestin.
Western blot
Immunoblot was performed as described previously. 12 Briefly, lysates were separated by 4-15% SDS-PAGE and electroblotted to PVDF membranes. After blocking with 5% nonfat dry milk, membranes were incubated with primary antibodies, followed by appropriate peroxidase-conjugated secondary antibodies. Primary antibodies used were anti-Smad 2/3, phosphor-Smad2/3, JNK, phospho-JNK (all from Cell Signaling Technology) and Vinculin (Thermo).
Real-time PCR
Total RNA was isolated from GSCs using Trizol reagent (Invitrogen) and first-strand DNA was synthesized using Superscript II (Invitrogen). Real-time PCR was conducted using SYBR green master mix (Applied Biosystems) in a StepOnePlus Real-time PCR System (Applied Biosystems). PCR primer sequences are TGFB1 (TGF-b1, forward: GGCTAC-CATGCCAACTTCTG, reverse: CCGGGTTATGCTGGTT-GTA), TGFB2 (TGF-b2, forward: TTCAGACACTCAGCA-CAGCA, reverse: TTGGGTGTTTTGCCAATGTA), TGFBR2 (TGF-b receptor II, forward: TGTGTCGAAAGCAT-GAAGGA, reverse: GGTCCCAGCACTCAGTCAAC) and GAPDH (forward: CAATGACCCCTTCATTGACC, reverse: GACAAGCTTCCCGTTCTCAG).
Sphere formation assay
To measure clonogenicity of GSCs, sphere formation assay was performed as described previously. 7 Briefly, 1 or 5 cells/ well were seeded into 96 well plates with TbR inhibitor or DMSO control, and spheres (>80 lm in diameter) were counted 12-14 days later.
Cell viability and cell count assay
Dissociated GSCs were plated in triplicate in 96-well plates and treated with drug or virus the next day and incubated at 378C for 5 days. Cell viability was measured by incubating with MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Sigma) for 2-4 hr and absorbance measurement at 490 nm on a plate reader. For cell count assay, GSCs were plated in 24-well plates and treated with TbR inhibitor and virus for 5 days. Viable cells that exclude trypan blue were counted on a hemocytometer. 
Luciferase assay
GSCs were plated into 96-well plates in triplicate and next day treated with drug and G47D-Us11fluc as indicated. Twenty four hours postinfection, D-Luciferin (Gold Biotechnology) was added to cells to 1 mM and luminescence was immediately measured on a BioTek Synergy HT multipurpose plate reader.
Chou-Talalay synergy analysis
The interaction of TbR inhibitors and virus on GSCs in vitro was determined with Chou-Talalay analysis 31 as described in
Refs. 12,32.
Caspase 3/7 activity assay
GSCs were plated at 5000 cells per well into 96-well plates and treated with drug and virus. Twenty four hours later, activation of the execution caspases 3/7 was measured by the Caspase-Glo 3/7 assay kit (Promega), following the manufacturer's instructions.
Treatment studies in orthotopic GSC tumor models
One hundred thousand MGG31 GSCs (in 3 ll) were stereotactically implanted into the right cerebrum of anesthetized 7-8-week-old female SCID mice (2.3 mm lateral of bregma, 2.5 mm deep from dural surface). Mice were randomized and assigned to 4 treatment arms (N 5 6/group): (i) control (vehicle and PBS), (ii) vehicle and MG18L, (iii) galunisertib and PBS and (iv) combination of MG18L and galunisertib. Galunisertib (100 mg/kg) or vehicle was given by oral gavage daily from Day 7-16. MG18L (1 3 10 6 pfu/3 ll) or PBS was injected stereotactically into the tumors on Day 9. Mice were followed for health status with body weight measurement 2-3 times a week. Mice were euthanized when they developed significant neurological deficits or general condition deterioration (>15% body weight loss). Survival was analyzed by using the Kaplan-Meier method. All the animal procedures were approved by the IACUC at Massachusetts General Hospital.
Statistical analysis
Student's t test (two-sided) was used to compare 2 groups. Statistical differences of animal survival were determined by log-rank test. p values <0.05 were considered significant. Statistical analyses were done with Excel and Graph Pad Prism.
RESULTS
Establishment of recurrent GSCs-based orthotopic xenograft models
To develop therapeutic strategies for recurrent GBM, we first established a panel of patient-derived GSC-based xenograft models of recurrent GBM that are based on neurosphereforming stem-like GBM cells. By applying the stem cell enriching culture methodology that enabled us to establish a large panel of primary GSC lines from newly diagnosed GBM, 7 we were able to establish 8 orthotopic recurrent GBM (recGBM) PDX models (Fig. 1a) . The recurrent GBM models demonstrated highly variable in vivo phenotypes: human specific nestin staining revealed that 4 lines (MGG24R, 45, 50 and 111R) exhibited extensive tumor invasiveness/migration and infiltration to brain parenchyma, 1 line (MGG91) showed semi-invasiveness, while the other 3 lines (MGG31, 85 and 123) showed a nodular phenotype with relatively discrete tumor-brain borders (Fig. 1a) . One of the nodular recGSCs, MGG85, displayed a characteristic sarcomatous histology ( Supporting Information, Fig. S1 ). MGG123 was previously described and contained pseudopalisading necrosis with a hypoxic microenvironment. 33 Genetically, MGG24R, 45, 50 and 111R had EGFR amplification, with MGG24R having the EGFRvIII mutant. All these EGFR-amplified lines were invasive in vivo, in line with the reported function of EGFR in promoting invasiveness of GBM. 34, 35 MGG45 and 50 had PTEN mutations, and MGG85 gliosarcoma had a TP53 mutation (p.Arg248Trp).
Mesenchymal-like phenotype and activated TGF-b pathway in recurrent GSCs
CD44 has been shown to be a representative marker of the mesenchymal subtype of GBM. [36] [37] [38] We therefore used CD44 IHC as a surrogate of a mesenchymal phenotype of GBM to characterize our tumor models. Tumor cells were strongly immunopositive for CD44 in all the recGBM models tested, while the newly diagnosed GSC xenograft of the proneural subtype (MGG8) was negative (Fig. 1b) . Another mesenchymal marker YKL-40 was immunopositive in the majority of the recGBM models, although staining was variable and typically patchy ( Supporting Information, Fig. S1 ). TGF-b signaling pathway has been implicated in epithelial-tomesenchymal transition (EMT) in cancer 16, 39, 40 and mesenchymal GBM. 38 RT-PCR analysis of TGF-b1, 2 and TbRII showed a tendency toward increased expression of these components of the TGF-b signaling pathway in our recGSC lines compared with newly diagnosed GSCs in vitro (Fig. 1c,  Supporting Information, Fig. S2A ). Furthermore, most of the recGSC lines had activation of the canonical TGF-b signaling in vitro as shown by phosphorylated forms of the TbR downstream signaling molecules Smad2 and Smad3 (pSmad2/3) in western blots (Fig. 1d) .
As these recGSCs were isolated from recurrent GBM having failed the standard of care radiation and the alkylating agent temozolomide (TMZ), they were expected to be resistant to temozolomide in vitro. Indeed, in vitro cell viability assays of the recGSCs demonstrated resistance to TMZ, with IC50 values typically >400 lM, as opposed to some of our previously characterized TMZ-sensitive primary GSC lines (MGG4 and MGG8) (Fig. 1e and Supporting Information, Table) . Thus we established a set of orthotopic GBM models generated from recurrent GSCs that display a mesenchymal phenotype and have an activated TGF-b pathway.
Suppression of TGF-b pathway decreased clonogenicity and viability of recurrent GSCs
The TGF-b signaling pathway has been shown to play a role in the maintenance of GSC 21, 22 ; however, its role in recGSCs is unknown. We therefore tested small molecule inhibitors that selectively target TbRI kinase for their impact on recGSC phenotypes in vitro. Supplementation of recombinant TGF-b1 to stem cell culture media potently activated pSmad2/3 in recGSCs (Fig. 2a) . Exposure of recGSCs to TbR inhibitors-SB431542, LY2109761 and galunisertib-almost completely shut down p-Smad2/3 in the presence or absence of TGF-b1 (Fig. 2a) . TbR inhibitors reduced cell viability of recGSCs typically at relatively high doses (>50 lM), with SB431542 generally being the most potent (Fig. 2b , Supporting Information, Table) . Clonogenic assays showed that SB431542 at noncytotoxic doses consistently inhibited sphere 
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formation of recGSCs (Fig. 2c, Supporting Information, Fig.  S2B ), supporting its activity on self-renewal of recGSCs. Thus, we show that TGF-b signaling promotes clonogenicity and viability of recGSCs.
oHSV infects, spreads and kills recurrent GSCs in vitro
We next investigated oHSV as a therapeutic for recGSCs. Infection of 6 recGSC lines with G47D-mCherry at low MOI resulted in the spread of oHSV within the spheres over 3-5 days postinfection (Fig. 3a) . We then determined the cytotoxicity of two clinically translatable oHSVs, G47D and MG18L, in recGSCs. Cell viability assays revealed that all 8 recGSC lines tested were susceptible to both oHSVs, with MG18L more efficacious in 4 lines (MGG31, MGG45, MGG91 and MGG111R) (Fig. 3b, Supporting Information, Table) .
Combination of oHSV and TGF-b receptor inhibitors synergistically kills recurrent GSCs
We then combined oHSV and TbR inhibitors and studied whether the two agents acted synergistically in killing recGSCs. Synergy was measured using the median-effect method of Chou-Talalay. 12, 31, 32 Across the different recGSC lines, the interaction of oHSV (G47D and MG18L) and TbR inhibitors (SB431542 and galunisertib) was synergistic at most fraction affected doses (Fig. 4ab and Supporting Information, Fig. S3 ). The beneficial impact of combination therapy was confirmed using viable cell count assays, where the oHSV/TbR inhibitor combination was superior to either monotherapy in mediating recGSC death (Fig. 4c) .
TGF-b receptor inhibition potently synergizes with oHSV in an orthotopic recurrent GSC xenograft model in vivo
We next asked whether combination therapy with oHSV and TbR inhibitor improves therapeutic efficacy in orthotopic GBM models generated from recGSCs. We chose galunisertib as the TbR inhibitor to use as this is currently being investigated in clinical trials for recurrent GBM (NCT01582269, NCT02423343 and NCT01220271). The MGG31 model was selected because of this line's consistent tumorigenic ability and small variation in survival times. Systemic treatment of galunisertib alone had no effect on survival of mice bearing orthotopic MGG31 xenografts, although 1 animal lived an additional 200 days (Fig. 5a ). Single intratumoral injection of MG18L significantly extended animal survival (75% prolongation of median survival over control), but all animals succumbed to tumor progression eventually. In contrast, combination treatment of systemic LY2157299 and local MG18L greatly extended survival, with 60% of the treated mice surviving long term with no evidence of tumor at autopsy on Day 400. We did not observe noticeable adverse events in any treatment group as evidenced by the lack of changes in body weight (Fig. 5b) . Thus, TbR inhibition dramatically potentiated the therapeutic efficacy of oHSV in an orthotopic recurrent GSC GBM model in vivo.
TGF-b receptor inhibition increases oHSV replication
We next asked whether increases in oHSV replication played a role in the benefit of combination therapy. We first used G47D-US11fluc since the activity of its reporter, firefly 
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luciferase, reflects late gene expression, which serves as a surrogate for virus replication. 30 There was a consistent increase in G47D-US11fluc-induced luciferase bioluminescence when infected recGSC lines were treated with TbR inhibitors SB431542 or galunisertib (Fig. 6a) . We next determined virus yields after infecting recGSC lines with G47D or MG18L with or without TbR inhibitors. At 48 hr postinfection, there was about a 1.5-2-fold and 2-6-fold increase in oHSV yields with G47D and MG18L, respectively, when co-treated with SB431542 or galunisertib (Fig. 6b, Supporting Information,  Fig. S4 ). Addition of recombinant TGF-b did not alter the replication of oHSV at the doses tested (Supporting Information, Fig. S5 ). These data indicate that TGF-b signaling inhibition leads to increased oHSV replication, which may underlie the synergistic interaction between oHSV and TbR inhibitors in recGSCs.
TGF-b receptor inhibition attenuates JNK and JNK inhibition increases oHSV replication
HSV infection activates the JNK-MAPK signaling pathway, which could regulate the survival of infected cells and induce apoptosis in some contexts. [41] [42] [43] Given an involvement of JNK signaling pathway in noncanonical signaling pathways triggered by TGF-b receptor activation, 44 we tested whether the JNK pathway played a role in the increased oHSV replication induced by TbR blockade. Exogenous recombinant TGF-b activated JNK phosphorylation in recGSCs, which was suppressed by TbR inhibitor SB431542 in vitro (Fig. 6c) . This result led us to test SP600125, a small molecule compound selectively inhibiting JNK, to determine the function of the JNK pathway in oHSV therapy of recGSCs. A noncytotoxic dose (600 nM) of SP600125 (Supporting Information, Fig. S6A ) blocked phosphorylation of JNK (Fig. 6d) , and increased luciferase expression upon G47D-US11fluc infection of recGSCs ( Supporting Information, Fig. S6B ). Virus yield assays confirmed that pharmacological inhibition of JNK enhanced yields of G47D and MG18L at 48 hr postinfection (Fig. 6e and Supporting Information, Fig. S6C ). SP600125 attenuated oHSV-induced caspase 3/7 activation in recGSCs, to a larger extent with MG18L, suggesting that SP600125 blockade of apoptosis in infected cells may contribute to increases in oHSV yields (Fig. 6f ).
DISCUSSION
The current standard of care for newly diagnosed GBM is unable to prevent tumor recurrence, and no effective therapy exists for recurrent GBM. Recurrent GBM is characterized by resistance to therapy, dissemination to distal regions of the CNS and aggressive behavior. 45 Such phenotypic traits of recurrent GBM are accompanied by molecular alterations, such as increased stemness marker expression, a hypermutator genotype caused primarily by TMZ and clonal evolution from the primary GBM. 45, 46 Preclinical models that represent clinical recurrent GBM will be useful for a better understanding of its unique biology and development of novel therapeutic approaches, which are sorely needed. However, infrequent biopsy for recurrent disease and the mixed presence of treatment effects (i.e., radiation necrosis), and low viable tumor cells limit the utility of patient specimens. Herein, we characterized a set of orthotopic recurrent GBM models that are based on GSCs derived from post-standard-of-care recurrent GBM. These models are variable in both in vivo phenotypes (invasive vs nodular phenotypes) and genotypes (e.g., EGFR and p53 status), likely reflecting the diverse molecular alterations in recGBM between patients. 46 Despite this heterogeneity, we observed consistent expression of the mesenchymal marker CD44 in our recGBM models. While EMT is a welldocumented process that is involved in malignant progression in cancer, EMT or an analogous phenomenon (mesenchymal shift) seems to occur in GBM recurrence. 36, 47, 48 Recently 
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Esaki et al. TGF-b has diverse functions in the pathogenesis of cancer including GBM 17 and plays a pivotal role in proliferation, invasion, therapy resistance, immune suppression and GSC maintenance in GBM. 17, 18 In addition, the TGF-b/Smad signaling pathway has been shown to promote EMT in cancer 16, 40 and TGFBR2 overexpression marks the mesenchymal subtype of GBM. 37 In our recurrent GBM models, TGFb signaling was active as TGF-b1, TGF-b2 and TbR were highly expressed and phosphorylation of canonical signaling molecules Smad 2 and 3 was present. Small-molecule inhibition of TbR blocked Smad2/3 phosphorylation and potently inhibited sphere formation of our recGSC, consistent with prior reports showing the critical role of TGF-b in GSC selfrenewal. 21, 22, 50 The TbR inhibitor LY2109761 has previously been demonstrated to block both TbR1 and TbR2 and have anti-GBM effects in GSC-derived orthotopic models. 23, 50 In our orthotopic recGSC-derived model, MGG31, we did not observe significant survival benefits with TbR inhibitor monotherapy.
The recGSC lines we tested were permissive to oHSV, as both G47D and MG18L exhibited the ability to infect, spread and kill our recGSCs in vitro. MG18L was more potent than G47D against 4 recGSCs (i.e., MGG31, 45, 91, and 111R), and single intratumoral injection showed significant monotherapy efficacy in an intracranial recurrent GBM model. Given that our recGSCs are resistant to the standard-or-care agent TMZ, the consistent potency of oHSV is particularly meaningful, and underscores the distinct cytotoxic mechanism employed by oHSV. Importantly, combination of oHSVs (G47D and MG18L) and TbR inhibitors (SB431542 and galunisertib) was synergistic in the treatment of multiple recGSCs in vitro. We found that inhibition of the TGF-b signaling significantly increased virus yield in multiple recGSCs, which may have contributed to synergy. Mechanistically, we observed that TbR inhibitor-mediated blockade of the JNK-MAPK pathway, one of the SMAD-independent pathways that TGF-b activates, 44 mediated viral replication enhancement. JNK signaling activation in HSV-infected cells is considered to be an innate defense mechanism, leading to caspase cascade activation and apoptosis of infected cells. 41, 42 A selective inhibitor of JNK (SP600125) similarly blocked JNK phosphorylation and increased oHSV amplification in recGSCs, suggesting a role for noncanonical TGF-b/JNK signaling in regulating oHSV replication in GBM. However, it is possible that SMAD-mediated transcriptional activation is also involved in modulating oHSV replication.
Despite the lack of in vivo activity of TbR inhibitor monotherapy in our recurrent GBM GSC model, galunisertib greatly potentiated the anti-GBM activity of oHSV MG18L in an orthotopic recurrent GBM GSC model, resulting in >60% long-term survivors compared with none in the single treatment groups. In vivo models in the current work are orthotopically transplanted xenografts in SCID mice that lack both T and B lymphocytes. Innate immune cells, particularly NK cells, have been shown to affect the outcome of oHSV therapy in xenografts by, in part, promoting the clearance of virus-infected cells and inhibiting intratumoral virus spread (reviewed in Refs. 51, 52) . TGF-b regulates the function of NK cells. 53 Han et al. reported that pretreatment of animals with TGF-b augmented the therapeutic effects of oHSV in both xenograft (human GBM) and syngeneic GBM models in vivo, phenocopying the outcomes of innate immune NK cell depletion. 54 On the other hand, Ilkow et al. demonstrated that TGF-b produced by tumor cells reprogrammed nearby cancer-associated fibroblasts and rendered them sensitive to oncolytic rhabdovirus infection, leading to enhanced overall virus replication. 55 Thus, GBM-produced TGF-b acts on different cell types and impacts the complex cellular cross-talk between GBM and stromal/immune cells within the tumor microenvironment, which likely affects oncolytic virus activity. Although these published reports and our current work seem discordant, the role of TGF-b in oHSV virotherapy may be context-and schedule-dependent. It is possible that both exogenous TGF-b and TGF-b inhibition could enhance oHSV therapy via different mechanisms.
Using clinically relevant orthotopic patient-derived GSC recurrent GBM models, we observed a potent, synergistic antitumor interaction between TbR inhibition and oHSV therapy that warrants further investigation as a treatment for refractory GBM. However, the limitations of our animal study include (i) treatment at an early time-point when tumors are perhaps only initiating and (ii) the use of a nodular (poorly invasive) GBM model. Further research, such as evaluation in additional models including invasive xenografts and immune-competent GBM models, is necessary to define the role of TGF-b and optimize the use of TbR inhibitor toward maximizing oHSV therapy for recurrent GBM.
